You are here

Rilutek prioritised for motor neurone disease

Rilutek prioritised for motor neurone disease
21st September 2009

Rilutek, the only drug known to slow the progression of motor neurone disease (MND), has been named as a priority supplement by a leading charity.

The MND Association named the drug - often known as Riluzole - as one which is difficult to obtain for sufferers.

It said medicines are more likely to be exported abroad as they can now fetch a higher price due to the fall in the pound against the euro.

The MND Association invited parties involved with Rilutek to a round-table discussion to ensure that everyone living with MND in the UK has access to the drug, with the organisations reporting back in November.

Dr Kirstine Knox, the chief executive of the MND Association, said: "We are grateful to all the organisations for attending this meeting and I am impressed by the commitment they have shown to ensuring that a stable and secure supply of Rilutek is available as soon as possible."

She added that Sanofi Aventis is particularly worthy of praise, as the organisation's contingency measures have proved "highly effective" so far by getting Rilutek to those needing it the most when it has been unavailable through regular channels.

Earlier this month, Mark Todd MP was voted by members of the MND Association to become the chairperson-elect of the Association's Board of Trustees.

Please click here for advice to help you find the right type of care.